Breaking News

J&J's two-drug combo blocked tumors in advanced multiple myeloma

December 9, 2025
By Adam Feuerstein, Angus Chen, Damian Garde, Katherine MacPhail

And on the last day of ASH, the sun shone once again. Thanks for joining us on this hematology-oncology journey. We hope you've enjoyed our coverage. Until next year, in New Orleans! 

IMG_0778

J&J's 'Tec-Dara' combo shines in multiple myeloma study

A two-drug regimen from Johnson & Johnson showed an unprecedented tumor-progression benefit compared to the standard of care for patients with relapsed or refractory multiple myeloma, according to results from a Phase 3 study presented today. 

In a study called MajesTEC-3, the two J&J drugs, Tecvayli and Darzalex, reduced the risk of tumor progression by 83% compared to standard multi-drug treatment —  achieving the study's primary efficacy goal. At three years, 83% of the patients treated J&J's "Tec-Dara" regimen were still alive without disease worsening compared to 30% of patients in the control arms. 

The study enrolled 587 patients with multiple myeloma who had experienced between 1 and 3 prior lines of therapy. 

"I think this is the best [risk reduction] we've seen in a Phase 3 clinical trial in multiple myeloma," said María-Victoria Mateos, a cancer researcher and physician at the University of Salamanca in Spain who presented the study. 

The combination also improved overall survival, reducing the risk of death by 55% in the study.

Serious infections were reported in 54% of patients on the Tec-Dara combination, worrisome enough to warrant investigators to add new mitigation measures in the middle of the trial. 

Tecvayli is a bispecific antibody that works by engaging a plasma cell protein called BCMA on one end and T cells on the other, helping the immune system find and attack myeloma cells. Darzalex is an antibody that targets the protein CD-38, which is also found on myeloma cells. 

"We're seeing potential cures for multiple myeloma, and I hope we can realize that soon with all the therapies coming, including this one," said Surbhi Sidana, a hematologist-oncologist at Stanford who was also an investigator on the trial.

One limitation of the study was that patients were ineligible for participation if they had already received Darzalex as part of their first-line treatment. This could raise questions about using Darzalex again when patients relapse, especially given the availability of a CAR-T therapy for these patients.


CDC cuts impact sickle-cell data collection program

Cuts at the Centers for Disease Control and Prevention have cast uncertainty over a decade-old effort to track sickle cell disease, leaving researchers without specialized federal support.

The CDC established the Sickle Cell Data Collection (SCDC) program to address a lack of research on the disease, which is the most commonly inherited blood disorder. Since its launch, the CDC has partnered with and funded states to collect data that can inform patient care and guide state and federal policy. 

That program was thrown into disarray on April 1, when all but two employees from the CDC's Division of Blood Disorders and Public Health Genomics were placed on administrative leave, including all staff who oversaw the SCDC program. 

In 16 states, teams continue collecting data on patients with sickle cell disease, but they are doing so with far less coordination from the CDC. 

"We're all taking responsibility for different chunks of the work that CDC used to do, and trying to do our best to bridge that gap," Sarah Reeves, principal investigator for the Michigan SCDC program, told STAT on the sidelines of the ASH meeting.

Reeves' team has produced a quantitative report that includes where people with sickle cell disease live, how many are seeing hematologists, immunizations gaps, and preventative care rates. They are partnering with the Michigan Department of Health and Human Services, which is making a five-year strategic plan for sickle cell treatment in the state. 

But Reeves worries the SCDC program may have lost some of its potential for broader-reaching impact, since the CDC staff was their main connection to external partners and policymakers at the national level. Future funding beyond this year also remains uncertain.

"Without having that coordination, we're doing our best, but we don't know all the players," Reeves said, adding that future funding is also uncertain.



A new way to treat a rare bleeding disorder

Patients with immune thrombocytopenia (ITP) who received Novartis' ianalumab in addition to standard therapy went longer without a serious bleeding episode compared with patients who received a placebo plus standard therapy, the company and researchers presented Tuesday.

ITP is an autoimmune disease in which the patient's immune system destroys platelets, cells that help promote blood clotting. The disease is rare, affecting an estimated 50,000 people in the U.S., and women more than men. 

In the Phase 3 study called VAYHIT2, ianalumab plus standard therapy showed a time to treatment failure of 13 months compared to 4.7 months for standard therapy, achieving the primary goal of the study. The study enrolled 152 patients with ITP who had either not responded to, or relapsed after standard first-line therapy. 

"As a hematologist, I'm glad that we have effective therapies for ITP, but they're not necessarily ideal for chronic disease management or long-term quality of life," said Adam Cuker of the Penn Blood Disorders Center and the study presenter. "This study shows that prolonged, durable responses to ITP treatment, without the need for ongoing therapy, are possible — and that's a huge advantage for patients."

Ianalumab works by blocking certain signals that causes B cells to overreact and attack the patient's own body.

In addition to being presented at the ASH meeting, the VAYHIT2 study was published in the New England Journal of Medicine. Novartis is studying ianalumab in multiple autoimmune disorders.


Removing chemo benefits patients with a genetic type of leukemia

A chemotherapy-free combination treatment outperformed a targeted drug and chemotherapy in patients with a certain genetic type of acute lymphoblastic leukemia, achieving the goal of a Phase 3 study. 

The study demonstrated that patients with the Ph+ subtype of ALL, a fast-growing leukemia, can achieve higher remission rates and a reduced risk of death from a course of treatment that omits chemotherapy, said Sabina Chiaretti of the Sapienza University of Rome and the lead study author. 

The study enrolled 236 adults with Ph+ ALL and randomized them to receive a combination of the targeted drug Iclusig and the immunotherapy Blincyto, or the targeted drug imatinib along with chemotherapy. 

At a median follow-up of almost two years, 87% of the patients who received the chemo-free regimen were alive without disease worsening compared to 71% in the control arm. The rate of death of 3.5% in the chemo-free arm versus 10% in the control arm. 

The safety profiles were consistent with those expected for each therapy involved in the study, with adverse events managed by reducing dosage. 


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Thanks for reading! Until ASH26 — Adam, Damian, and Katherine

Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of the weekly newsletter Adam's Biotech Scorecard.

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT's industry-leading events.

Katherine MacPhail is an editorial events programmer at STAT. 


Enjoying this newsletter? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments